Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SINTX TechnologiesSINT +0.32%27 Debt-to-Equity is 3.61 as of Mar. 2026, which is 962% above its 10-year median of 0.34. GuruFocus rates SINT with a GF Score™ of 27/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 705 Medical Devices & Instruments companies, SINTX Technologies ranks worse than 96.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SINTX Technologies's Debt-to-Equity or its related term are showing as below:
SINT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.34 Max: 3.61
Current: 3.61
During the past 13 years, the highest Debt-to-Equity Ratio of SINTX Technologies was 3.61. The lowest was 0.02. And the median was 0.34.
SINT's Debt-to-Equity is ranked worse than 96.88% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SINT: 3.61
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SINTX Technologies Debt-to-Equity Related Terms
SINTX Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SINTX Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SINT vs ALRTF, CODX, PMI: Debt-to-Equity Comparison
For the Medical Devices subindustry, SINTX Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SINTX Technologies Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SINTX Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SINTX Technologies (SINT) has a Debt-to-Equity of 3.61 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SINTX Technologies and its competitors. This is 962% above median its historical median of 0.34. Over the past decade, SINTX Technologies' Debt-to-Equity has ranged from 0.02 to 3.61. According to the industry distribution chart, SINTX Technologies ranks #683 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 96.9%.
Is SINTX Technologies' Debt-to-Equity too high?
SINTX Technologies' current Debt-to-Equity of 3.61 is 962% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 3.61. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. SINTX Technologies' value of 3.61 is 1469.6% above this industry median. Based on the distribution chart, SINTX Technologies ranks #683 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SINTX Technologies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SINTX Technologies' Debt-to-Equity compare to ALRTF and CODX?
According to the Medical Devices & Instruments industry distribution chart, SINTX Technologies ranks #683 out of 705 companies for Debt-to-Equity. This places SINTX Technologies in the lower half of its industry. The industry median Debt-to-Equity is 0.23. SINTX Technologies' value of 3.61 is 1469.6% above this benchmark. Historically, SINTX Technologies' own Debt-to-Equity has ranged from 0.02 to 3.61 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 0.23, SINTX Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SINTX Technologies's current Debt-to-Equity of 3.61 is 1469.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SINTX Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SINTX Technologies's current Debt-to-Equity is 3.61, which is 962% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SINTX Technologies stock overvalued right now?
Based on GuruFocus' analysis, SINTX Technologies (SINT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.57 — trading 946.7% above its estimated fair value. The current Debt-to-Equity is 3.61, which is 962% above median its 10-year median of 0.34 and 1469.6% above the Medical Devices & Instruments industry median of 0.23. SINTX Technologies' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SINTX Technologies (SINT), the current Debt-to-Equity is 3.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SINTX Technologies (SINT) Overvalued in 2026?
Based on GuruFocus' analysis, SINTX Technologies stock appears to be overvalued.
The current stock price of $1.57 is trading 946.7% above its estimated GF Value™ of $0.15.
GuruFocus considers SINTX Technologies to be Significantly Overvalued.
Key valuation signals for SINT:
Debt-to-Equity: 3.61 (962% above median its 10-year median of 0.34)
GF Value™: $0.15 vs. price of $1.57 (946.7% above fair value)
Industry Position: 1469.6% above the Medical Devices & Instruments median (#683 of 705)
No single metric tells the full story. See the SINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
27GF Score
Get the complete analysis for SINT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SINT has been successfully added to your 
